Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation
- 28 January 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Cancer and Metastasis Reviews
- Vol. 29 (1), 49-60
- https://doi.org/10.1007/s10555-010-9209-4
Abstract
KRAS and epidermal growth factor receptor (EGFR) are the two most frequently mutated proto-oncogenes in adenocarcinoma of the lung. The occurrence of these two oncogenic mutations is mutually exclusive, and they exhibit many contrasting characteristics such as clinical background, pathological features of patients harboring each mutation, and prognostic or predictive implications. Lung cancers harboring the EGFR mutations are remarkably sensitive to EGFR tyrosine kinase inhibitors such as gefitinib or erlotinib. This discovery has dramatically changed the clinical treatment of lung cancer in that it almost doubled the duration of survival for lung cancer patients with an EGFR mutation. In this review, we describe the features of KRAS mutations in lung cancer and contrast these with the features of EGFR mutations. Recent strategies to combat lung cancer harboring KRAS mutations are also reviewed.This publication has 99 references indexed in Scilit:
- Requirement for NF-κB signalling in a mouse model of lung adenocarcinomaNature, 2009
- Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1Nature, 2009
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell SurvivalCancer Cell, 2009
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras OncogeneCell, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Somatic mutations affect key pathways in lung adenocarcinomaNature, 2008
- Kras regulatory elements and exon 4A determine mutation specificity in lung cancerNature Genetics, 2008
- Characterizing the cancer genome in lung adenocarcinomaNature, 2007
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003